<DOC>
	<DOCNO>NCT01189279</DOCNO>
	<brief_summary>This study investigate safety , tolerability , pharmacokinetics new formulation bimatoprost follow topical application patient alopecia . Two formulation bimatoprost investigate Part 1 third formulation bimatoprost investigate Part 2 . Part 2 begin Part 1 complete .</brief_summary>
	<brief_title>Safety Pharmacokinetics Study New Formulation Bimatoprost Patients With Alopecia</brief_title>
	<detailed_description />
	<mesh_term>Alopecia</mesh_term>
	<mesh_term>Alopecia Areata</mesh_term>
	<mesh_term>Bimatoprost</mesh_term>
	<criteria>Males moderate malepattern baldness ( androgenic alopecia ) Females moderate female pattern hair loss Nonsmoker smoker least 30 day abstinence smoking/using nicotinecontaining product Any dermatological condition scalp androgenic alopecia ( male ) female pattern hair loss ( female ) Use bimatoprost prostaglandin analog within 3 month Prior use scalp hair growth treatment ( eg , finasteride , minoxidil ) within 6 month Any prior hair growth procedure ( eg , hair transplant laser ) Blood donation equivalent blood loss within 90 day History alcohol drug addiction</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>June 2013</verification_date>
</DOC>